The CHADL (chondroadherin-like) antibody targets a protein belonging to the small leucine-rich repeat proteoglycan (SLRP) family, which plays critical roles in extracellular matrix (ECM) organization and cellular signaling. CHADL shares structural homology with chondroadherin (CHAD), a cartilage-specific SLRP involved in collagen fibrillogenesis and chondrocyte adhesion. Initially identified through genomic analyses, CHADL is expressed in cartilage and other connective tissues, though its precise biological functions remain less characterized compared to other SLRPs like decorin or lumican. Studies suggest CHADL may regulate ECM remodeling by interacting with collagen fibrils or growth factors, influencing tissue biomechanics and cellular responses during development or repair. Its expression is often dysregulated in osteoarthritis, intervertebral disc degeneration, and certain cancers, implicating it in disease pathogenesis. CHADL antibodies are primarily used as research tools to investigate its localization, expression patterns, and molecular interactions in health and disease. Recent interest has grown in exploring CHADL as a potential biomarker for cartilage degradation or as a therapeutic target. However, further studies are needed to fully elucidate its mechanisms and translational relevance.